Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (201)	11/21/1997 10:17:00 AM
From: flickerful	Respond to of 756

dear kamikaze... i thought those were single passenger planes? i seem to be co-pilot: the ground is getting closer faster... let me look into the fund positions.

To: 5,17,37,5,101,... who wrote (201)	11/21/1997 10:23:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

IVX, flickerful, a chart. geocities.com The chart shows the movement in Sept. that you mentioned. Note the break from the severely narrowed Bollingers (basing pattern) and the slew of accompanying indicators. A somewhat more benign result in October. It is oversold right now and will most likely get a pop if and when the indicators pull out of oversold. Note the Bollingers are beginning to narrow ...IVX has begun a basing pattern that started around Nov. 10...when it pulled sideways from a down trendline (I did not draw it in). The healthiest pattern for IVX (news notwithstanding) would be a longer basing pattern here ( near the low) with the narrowed Bollingers....and then the subsequent pop and reversal that so frequently occurs. For those confident of IVX, Paxene et al this is not a bad point to consider an entry...though personally I would wait for a little indicator confirmation. Good luck, Stan ~~~~~~~~~~~~~~~here's a link to stan's thread and some earlier ivax ( and idti, among others) discussion. techstocks.com

To: 5,17,37,5,101,... who wrote (201)	11/22/1997 7:10:00 AM
From: flickerful	Respond to of 756

To: +flickerful (1300 ) From: +stan s. Friday, Nov 21 1997 11:50PM EST Reply #1301 of 1301 IVX, a couple of momentum buy signals today. Basing for now, managed to close over support. Bollingers continue to narrow... geocities.com

To: 5,17,37,5,101,... who wrote (201)	11/22/1997 7:39:00 AM
From: flickerful	Respond to of 756

Friday November 21 12:48 PM EST Clinton Signs FDA Reform Act WASHINGTON (Reuters) -- The Food and Drug Administration bill signed into law by President Clinton Friday aims to speed up approval of drugs and medical devices. Congress worked on FDA legislation for several years, and this bill reflects numerous compromises between Republicans and Democrats. It has broad industry support and many patient advocacy groups praise its provisions for making new drugs available more swiftly to seriously ill people. Here are some of its major provisions: -- Extension of the Prescription Drug User Fee Act (PDUFA), which passed Congress in 1992 and would have expired this year. Under PDUFA, pharmaceutical companies pay fees that the FDA uses to help speed up drug safety and efficacy reviews. Drug industry groups say it cut approval times in half and will raise another $600 million over the next five years. -- Medical devices, which cover everything from tongue depressors to pacemakers. Under an expanded pilot project, independent but accredited outside experts will review the safety of certain, relatively low risk medical devices. The FDA will still review more complex devices. -- Off-label use. Once a drug is approved for a specific purpose, doctors have been able to prescribe it at their discretion for other treatments, so called "off-label" use. The new law sets clear rules for how drug companies can disseminate authoritative published research on off-label use, but if they do so they must also start the process of getting official approval for the additional use. -- Emergency access. The bill speeds up access to new but not yet approved drugs in life-threatening situations. -- "Fast-track" drugs. Expanding a program that already applies to some AIDS and cancer drugs, the bill takes steps toward more rapid approval of breakthrough drugs for serious or life-threatening illnesses. -- Cosmetics. After a prolonged fight over whether states could enact their own labeling requirements, a compromise was reached. The states could still regulate cosmetics and other over-the-counter items, except in cases where the FDA's relatively small cosmetics program has set a national policy. -- Clinical trial data banks. The bill sets up a national data bank on clinical trials for serious diseases. It would help find experimental therapies for patients without comparable treatment. -- Pediatrics. The bill gives the incentive of a six-month patent right extension if a pharmaceutical company researches how a drug should be used for children. ------------------------------------------------------------------------ Copyright c 1997 Reuters Limited. All rights reserved. Republication or redistribution of Reuters